Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kane Biotech Inc. V.KNE

Alternate Symbol(s):  KNBIF

Healthcare Biotechnology
Kane Biotech Inc. is a Canada-based biotechnology company. The Company is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. It has a portfolio of biotechnologies and products, which includes StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactiv+, DermaKB and DermaKB Biofilm. Its... see more

Recent & Breaking News (TSXV:KNE)

Kane Biotech Announces First Quarter 2019 Earnings Conference Call and Business Update

GlobeNewswire May 16, 2019

Kane Biotech Provides Update on Exclusive License and Distribution Agreement with Dechra Veterinary Products

GlobeNewswire April 30, 2019

Kane Biotech Announces New Sales Representation by SLA Brands

GlobeNewswire April 24, 2019

Kane Biotech Announces Granting of Options

GlobeNewswire April 17, 2019

Kane Biotech Announces Fourth Quarter and Full Year 2018 Financial Results

GlobeNewswire March 25, 2019

Kane Biotech Schedules Full Year 2018 Earnings Conference Call and Business Update

GlobeNewswire March 20, 2019

Kane Biotech Signs Distribution Agreement and Secures First Order from China

GlobeNewswire February 19, 2019

Eastern Missouri Court Rules in Favor of Kane Biotech in Lawsuit Against Nestle Purina

GlobeNewswire February 4, 2019

Kane Biotech Expands Previously-Announced Single Largest Order of bluestem™ Products

GlobeNewswire January 30, 2019

Kane Biotech to Host Investor Town Hall Webcast and Conference Call

GlobeNewswire January 25, 2019

Kane Biotech Secures Largest Single Order of bluestem™ products

GlobeNewswire January 24, 2019

Kane Biotech Positions DispersinB® for Wound Care treatment in United States: Applies for U.S. Army Medical Research Funding and renews commitment to Rutgers University

GlobeNewswire January 17, 2019

Kane Biotech Launches Four New bluestem™ Products

GlobeNewswire December 12, 2018

Kane Biotech Announces Third Quarter 2018 Financial Results

GlobeNewswire November 14, 2018

Kane Biotech Announces Extension of Warrants

GlobeNewswire November 12, 2018

Kane Biotech Records Significant Online Sales Growth from Amazon

GlobeNewswire November 9, 2018

Kane Biotech Schedules Third Quarter 2018 Earnings Conference Call and Business Update

GlobeNewswire November 8, 2018

Kane Biotech Senior Management Purchases 1.9 Million Shares

GlobeNewswire November 7, 2018

Kane Biotech Appoints Dr. Gordon Guay as Chief Scientific Officer

GlobeNewswire November 5, 2018

Kane Biotech Announces New Manufacturing Partner for bluestem™ Product Line

GlobeNewswire October 17, 2018